Phase 2 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with non-small cell lung cancer, confirmed through a tissue or cell sample.
- People with stage II or stage III non-small cell lung cancer that cannot be removed by surgery, and who have already received treatment before surgery (neoadjuvant therapy).
- People with a general health and activity level rated as 0, 1, or 2 on a standard medical scale (meaning able to carry out daily activities with little to no limitations).
- People whose organs (such as liver and kidneys) and bone marrow are functioning at an adequate level.
Who may not be able to join:
- People who have had radiotherapy in the past.
- People who have experienced immune-related lung inflammation (pneumonitis) rated at grade 2 or higher during previous treatment.
- People whose cancer in a specific area still requires surgery.
- People who have had another separate primary cancer at some point.
- People with a history of an active primary immune system deficiency condition.
- People whose tissue samples show a mixed type of cancer containing both small cell and non-small cell lung cancer.
- People who are still experiencing side effects from chemotherapy or radiotherapy received before the study that have not been resolved (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Lei Deng, MD, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phone: 010-87787692
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence and severity of grade 3 and above radiation esophagitis; Incidence and severity of grade 2 and above radiation pneumonitis
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.